Avalo Therapeutics (AVTX) CFO receives 39,900 PSU-linked shares in equity award
Rhea-AI Filing Summary
Avalo Therapeutics, Inc. disclosed that its Chief Financial Officer, Christopher Ryan Sullivan, acquired 39,900 shares of Common Stock on May 21, 2026 in a grant/award transaction with a stated price of $0.0000 per share. Following this award, he directly holds 40,323 shares of Common Stock.
According to the accompanying disclosure, these shares relate to performance stock units (PSUs) originally granted on August 19, 2025, each representing a contingent right to receive one share of Common Stock upon achievement of specified performance goals. The Compensation Committee certified achievement of those goals on May 21, 2026, and the shares subject to the PSUs are scheduled to fully vest on August 19, 2028, subject to Sullivan’s continued service through that vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 39,900 shares
Net Buy
1 txn
Insider
Sullivan Christopher Ryan
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 39,900 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 40,323 shares (Direct)
Footnotes (1)
- F1. Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date.
Key Figures
Shares acquired: 39,900 shares
Price per share: $0.0000 per share
Post-transaction holdings: 40,323 shares
+3 more
6 metrics
Shares acquired
39,900 shares
Grant/award of Common Stock on May 21, 2026
Price per share
$0.0000 per share
Reported transaction price for the award
Post-transaction holdings
40,323 shares
Common Stock directly held after the transaction
PSU grant date
August 19, 2025
Original grant date of performance stock units
Performance certification date
May 21, 2026
Compensation Committee certified performance goals
Full vesting date
August 19, 2028
Scheduled full vesting of PSU-related shares
Key Terms
performance stock units, PSUs, Compensation Committee, vesting
4 terms
performance stock units financial
"Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025."
Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.
PSUs financial
"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals."
PSUs are company shares promised to employees or executives that only become actual stock if the business hits specific performance targets over a set period. For investors, PSUs matter because they link pay to measurable outcomes — similar to a conditional bonus that converts into ownership — which can influence management decisions, dilution of shares, and signals about confidence in future results.
Compensation Committee financial
"On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals."
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
vesting financial
"As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Avalo Therapeutics (AVTX) CFO report in this Form 4?
Avalo Therapeutics’ CFO, Christopher Ryan Sullivan, reported an acquisition of 39,900 shares of Common Stock on May 21, 2026. The award was recorded at a price of $0.0000 per share and increased his direct holdings to 40,323 shares after the transaction.
What are the performance stock units (PSUs) mentioned for Avalo Therapeutics (AVTX) CFO?
The CFO’s PSUs are equity awards granted on August 19, 2025, each representing a contingent right to one Common Share. They become earned upon achieving specified performance goals and then convert into shares according to the vesting schedule described in the disclosure.
When were Avalo Therapeutics (AVTX) CFO’s PSU performance goals certified?
The Compensation Committee certified achievement of the CFO’s PSU performance goals on May 21, 2026. This certification confirms that the performance conditions were met, allowing the PSU-related shares to follow the stated vesting timeline, subject to continued service requirements.
Was the Avalo Therapeutics (AVTX) CFO’s Form 4 transaction an open-market purchase?
No, the Form 4 transaction reflects a grant or award acquisition, not an open-market purchase. The filing shows 39,900 shares acquired at a price of $0.0000 per share, tied to previously granted performance stock units rather than a market buy.
AI-generated analysis. How Rhea-AI works. Not financial advice.
